Evidence map›Paper›PMID 42031495›Full record

ArticleBMJ open2026

Refining

Christina A Muzny, Rebecca A Lillis, Steven E Chavoustie, Janeen L Arbuckle, Olivia T Van Gerwen, Momi Sagoe, Akilesh Rahul Kandregula, Sudesh Srivastav, Patricia J Kissinger

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06261840 (Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06261840 phase4recruitingnot on this map

Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole

TypeinterventionalSponsorTulane UniversityRan2025 to 2029Enrolled1,200ConditionsTrichomonas Vaginitis, Bacterial VaginitisArmsMetronidazole 500 mg, Secnidazole 2000 MG
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christina A MuznyThe University of Alabama at Birmingham Division of Infectious Diseases, Birmingham, Alabama, USA.ORCID http://orcid.org/0000-0002-4005-3858
Rebecca A LillisDepartment of Medicine, Section of Infectious Diseases, LSU CrescentCare Sexual Health Center, Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, USA.
Steven E ChavoustieHealthcare Clinical Data Inc, Miami, Florida, USA.
Janeen L ArbuckleThe University of Alabama at Birmingham Department of Obstetrics and Gynecology, Birmingham, Alabama, USA.
Olivia T Van GerwenThe University of Alabama at Birmingham Division of Infectious Diseases, Birmingham, Alabama, USA.
Momi SagoeDepartment of Epidemiology, Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
Akilesh Rahul KandregulaDepartment of Epidemiology, Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
Sudesh SrivastavDepartment of Epidemiology, Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
Patricia J KissingerDepartment of Epidemiology, Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA kissing@tulane.edu.ORCID http://orcid.org/0000-0002-2038-9151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMETHODS AND ANALYSIS: This is a multi-centred open-label effectiveness trial comparing oral multi-dose MTZ (500 mg twice daily for 7 days) to 2 g of single-dose oral SEC. This trial aims to enrol 1200 ETHICS AND DISSEMINATION: This protocol is approved through a single Institutional Review Board (IRB) mechanism by the Tulane Human Research Protection Programme (Protocol # 2024-101 SPHTM). External relying sites are the UAB IRB (including both the UAB Sexual Health Research Clinic and Gynaecology Clinics; Protocol ID IRB-300012617), the LSUHSC-NO IRB (LSU-CrescentCare Sexual Health Centre; Protocol ID 6979) and the Advarra IRB (Healthcare Clinical Data Inc; Protocol ID Pro00085531). This study is also approved for referral purposes only by the Research Review Committee at the Jefferson County Department of Health (JCDH) Sexual Health Clinic in Birmingham, AL (JCDH Research Number 2024-03). Study findings will be presented in scientific conferences and peer-reviewed journals, shared with treatment advisory boards, as well as disseminated to providers and patients in communities of interest. The study Data Safety and Monitoring Board (DSMB) will meet twice a year to review patient safety data and study progress and provide recommendations on the study's continuation or modification. TRIAL REGISTRATION NUMBER: NCT06261840.

Indexed as

Antiprotozoal AgentsMetronidazoleTrichomonas InfectionsTrichomonas vaginalisTrichomonas VaginitisAdministration, OralAdultFemaleHumansMaleRandomized Controlled Trials as TopicTreatment OutcomeAntiprotozoal AgentsMetronidazolesecnidazoleInfectious diseases & infestationsREPRODUCTIVE MEDICINESexually Transmitted Disease

Identifiers

PMID42031495
PMCPMC13110672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.